Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Squamous Cell Carcinoma of Head and Neck 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Stomach Neoplasms 2Nasopharyngeal Carcinoma 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Lung Neoplasms 2Carcinoma, Hepatocellular 2Advanced Solid Tumor 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Rectal Neoplasms 1Pheochromocytoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Paraganglioma, Extra-Adrenal 1Pancreatic Neoplasms 1Pancreatic Adenocarcinoma Metastatic 1Osteosarcoma 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma 1Gynecological Cancer 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Esophageal Squamous Cell Carcinoma 1

Interventions

Cisplatin 127Gemcitabine 71Radiotherapy, Intensity-Modulated 61toripalimab 39Capecitabine 37Docetaxel 36Fluorouracil 35Radiotherapy 24camrelizumab 23Drug Therapy 22nimotuzumab 18spartalizumab 13pembrolizumab 13nedaplatin 12Chemoradiotherapy 12sintilimab 11apatinib 11Induction Chemotherapy 11Immune Checkpoint Inhibitors 11tislelizumab 10Nivolumab 10Magnetic Resonance Spectroscopy 10Specimen Handling 9Radiation 9Cetuximab 9Carboplatin 9endostar protein 8Paclitaxel 8Bevacizumab 8anlotinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Nasopharyngeal Carcinoma × penpulimab × Clear all
NCT05563480 2026-04-07

TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Completed
47 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT04974398 2025-04-13

A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Akeso

Phase 3 Active not recruiting
296 enrolled 1 FDA
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡